VK0214
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)
Conditions
Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)
Trial Timeline
Jun 22, 2021 → Nov 8, 2024
NCT ID
NCT04973657About VK0214
VK0214 is a phase 1 stage product being developed by Viking Therapeutics for Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD). The current trial status is completed. This product is registered under clinical trial identifier NCT04973657. Target conditions include Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD).
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04973657 | Phase 1 | Completed |
Competing Products
1 competing product in Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PXL770 | Poxel | Phase 2 | 44 |